- Home
- GDEV vs PCRX Comparison
GDEV vs PCRX Comparison
Compare GDEV & PCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GDEV
- PCRX
- Stock Information
- Founded
- GDEV 2009
- PCRX 2006
- Country
- GDEV Cyprus
- PCRX United States
- Employees
- GDEV N/A
- PCRX N/A
- Industry
- GDEV EDP Services
- PCRX Biotechnology: Pharmaceutical Preparations
- Sector
- GDEV Technology
- PCRX Health Care
- Exchange
- GDEV Nasdaq
- PCRX Nasdaq
- Market Cap
- GDEV 520.6M
- PCRX 604.7M
- IPO Year
- GDEV N/A
- PCRX 2011
- Fundamental
- Price
- GDEV $26.00
- PCRX $16.52
- Analyst Decision
- GDEV Buy
- PCRX Buy
- Analyst Count
- GDEV 2
- PCRX 10
- Target Price
- GDEV $70.00
- PCRX $26.60
- AVG Volume (30 Days)
- GDEV 6.9K
- PCRX 545.3K
- Earning Date
- GDEV 11-14-2024
- PCRX 11-06-2024
- Dividend Yield
- GDEV N/A
- PCRX N/A
- EPS Growth
- GDEV N/A
- PCRX N/A
- EPS
- GDEV 2.48
- PCRX N/A
- Revenue
- GDEV $443,165,000.00
- PCRX $694,957,000.00
- Revenue This Year
- GDEV N/A
- PCRX $4.59
- Revenue Next Year
- GDEV $6.12
- PCRX N/A
- P/E Ratio
- GDEV $10.50
- PCRX N/A
- Revenue Growth
- GDEV N/A
- PCRX 4.40
- 52 Week Low
- GDEV $19.00
- PCRX $11.16
- 52 Week High
- GDEV $42.76
- PCRX $35.95
- Technical
- Relative Strength Index (RSI)
- GDEV 39.77
- PCRX 44.28
- Support Level
- GDEV $24.30
- PCRX $16.11
- Resistance Level
- GDEV $32.60
- PCRX $18.34
- Average True Range (ATR)
- GDEV 2.94
- PCRX 0.83
- MACD
- GDEV -1.03
- PCRX -0.17
- Stochastic Oscillator
- GDEV 9.21
- PCRX 5.33
About GDEV GDEV Inc.
GDEV Inc is a gaming and entertainment holding company that oversees a portfolio of studios focused on developing and publishing live-service games across a range of platforms and genres. Its portfolio includes studios specializing in mobile, browser, and PC games, as well as captivating IPs spanning various genres.
About PCRX Pacira BioSciences Inc.
Pacira BioSciences Inc is a provider of non-opioid pain management and regenerative health solutions dedicated to advancing and improving outcomes for healthcare practitioners and their patients. The company has three commercialized non-opioid treatments: EXPAREL a long-acting, local analgesic currently approved for postsurgical pain management; ZILRETTA, an extended-release, intra-articular, corticosteroid injection indicated for the management of osteoarthritis; iovera, a novel, handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.